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Essentials
• FXa I16L is a recombinant zymogen-like variant of activated coagulation factor X (FXa).
• A phase 1 dose escalation clinical trial of FXa I16L was conducted in healthy adults.
• FXa I16L was safe and tolerated at doses up to 5 lg/kg; no dose-limiting toxicity was observed.
• Data support further development of FXa I16L for patients with acute hemorrhagic conditions. Summary. Background: FXa I16L (PF-05230907) is a zymogen-like variant of activated factor X (FXa). It shows enhanced resistance to inactivation by endogenous inhibitors as compared with wild-type FXa, and restores hemostatic activity in non-clinical models of various bleeding conditions. Objectives: To evaluate the safety, pharmacokinetics and pharmacodynamics of FXa I16L by performing a phase 1, first-in-human, dose-escalation clinical trial in healthy adult volunteers. Methods: Participants were assigned to one of six ascending single-dose cohorts (0.1, 0.3, 1, 2, 3 or 5 lg kg À1 ), each planned to comprise six volunteers treated with FXa I16L and two treated with placebo. Assessments included safety monitoring, pharmacokinetic and pharmacodynamic (PD) analyses, and immunogenicity testing. Results: The trial enrolled 49 male volunteers. Administration of a single intravenous bolus dose of FXa I16L was safe and tolerated at all dose levels tested, with no dose-limiting toxicity or serious adverse events. FXa I16L plasma levels appeared to increase dose-proportionally, with a half-life of~4 min. Treatment-related PD changes were observed for activated partial thromboplastin time, thrombin generation assay, thrombin-antithrombin complexes, prothrombin fragment 1 + 2, and D-dimer. One volunteer had a weak and transient non-neutralizing antidrug antibody response, which did not cross-react with native FX or native FXa. Conclusions: FXa I16L was safe and tolerated, and showed a pharmacologic effect in healthy adults when administered at doses up to 5 lg kg À1 . The safety profile, pharmacokinetics and pharmacodynamics observed in this clinical trial support the further development of FXa
Introduction
Effective therapies are needed to rapidly control bleeding in many clinical situations [1] . Activated factor X (FXa) occupies a central position in the blood coagulation cascade, and activates prothrombin to thrombin [1, 2] . Administration of wild-type (WT) FXa, which is an attractive approach to restoring hemostasis, is limited by its short half-life (< 1-2 min), resulting from inactivation by circulating serine protease inhibitors, such as antithrombin (AT) [2] [3] [4] [5] [6] . Furthermore, FXa that escapes inhibition has the potential to cause uncontrolled systemic coagulation [2, [7] [8] [9] . FXa I16L (PF-05230907) was designed to circumvent these limitations. Owing to an alteration in the conformational transition from zymogen to active protease, it shows reduced activity and resistance to inactivation by endogenous inhibitors in the absence of activated FV (FVa), and a longer half-life in non-clinical studies [2, 5] . Similarly to that of WT FXa, binding of FVa facilitates the transition of FXa I16L to an active conformation, restoring its hemostatic activity [2, 5] . Assembly of FXa I16L into the active complex with FVa is sensitive to inhibition by activated protein C [2] . FXa I16L showed procoagulant function in vitro in normal human plasma and in plasma from individuals with hemophilia [2, 10] , and has improved hemostasis in various non-clinical bleeding models [1, 5] . Furthermore, the requirement for FVa to restore FXa I16L protease function may localize procoagulant function to the site of injury [2, 5, 10] . FXa I16L (PF-05230907) is being developed as a singleuse hemostatic agent for the acute treatment of patients with spontaneous intracerebral hemorrhage (ICH), which is a major cause of death and disability [11, 12] . We report here the results of the first clinical study with FXa I16L . This clinical trial was conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of FXa I16L administered at single escalating dose levels in healthy adult volunteers.
Materials and methods

Trial design
This randomized, placebo-controlled, double-blind (sponsor and pharmacist unblinded) clinical trial enrolled healthy male adult volunteers aged 18-35 years, with no hereditary, acquired or demographic risk factors for thrombosis. Platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and hepatic and renal function had to be within laboratory reference ranges.
Six escalating dose levels were planned (cohorts 1-6). Each cohort included six volunteers receiving a single intravenous bolus dose of FXa I16L and two volunteers receiving placebo. Two volunteers were first randomized (1 : 1) to receive active treatment or placebo for all cohorts. For the first two cohorts, following a review of safety data up to 72 h postdose, six volunteers were then randomized (5 : 1) to receive FXa I16L or placebo. For subsequent cohorts, following review of data from the initial two volunteers, a sequential dosing stagger was then performed, with each remaining volunteer receiving FXa I16L or placebo (5 : 1). Volunteers were inpatients for ≥ 72 h postdose, returning for follow-up at 6, 14, 28 and 42 days, with additional visits at 6 months and 9 months if an antidrug antibody (ADA) immune response was observed. Dose escalation occurred if the preceding dose level was well tolerated and did not exceed the pharmacokinetic (PK) exposure limit, and after satisfactory review (by investigator, sponsor, and external data monitoring committee) of safety findings.
This trial was conducted at a Clinical Research Unit in Brussels, Belgium, in accordance with Good Clinical Practice and International Council for Harmonization guidelines, and applicable national and local laws and regulations. The protocol was approved by an independent ethics committee. All volunteers provided written informed consent before participation. The trial is registered at www.clinicaltrials.gov (identifier: NCT01897142).
Safety analyses
Safety monitoring included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), physical examinations, vital signs, electrocardiograms (ECGs), safety laboratory tests, and thrombosis clinical probability scores [13] . The occurrence of two or more clinically significant abnormal laboratory, ECG or vital sign findings that met quantitative stopping rule criteria would trigger a stop in dosing at the respective dose level and/or at dose escalation.
PK and pharmacodynamic (PD) analyses
PK specimens were collected prior to dosing and at 2, 5, 15 and 40 min and 1, 2 and 4 h postdose. Plasma FXa I16L concentrations were measured with a validated ELISA method. The PK data were analyzed with standard non-compartmental methods. Concentrations below the level of detection were set to 0 for PK analysis. PD specimens were collected prior to dosing (baseline) and at 2, 5, 15 and 40 min and at 2, 4 and 24 h and, for some assays, at 48 h postdose.
Laboratory parameters
Laboratory safety parameters included hematology, chemistry, urinalysis, cardiac troponin I, tissue factor pathway inhibitor, platelet count, fibrinogen, AT, protein S activity (STA-Staclot Protein S; Diagnostica Stago, Parsippany, NJ, USA), and D-dimer (day 7 and later). Parameters used to assess both safety and pharmacodynamics included PT/ International Normalized Ratio (INR), APTT, and protein C activity (STA-Staclot Protein C, Diagnostica Stago). The PD parameters included thrombin-antithrombin (TAT) complexes, prothrombin fragments 1 + 2 (F 1 + 2 ), FV activity, and D-dimer. Chromogenic protein C (STA-Stachrom Protein C) and free protein S (STA-Liatest Free Protein S) assays were performed for the last two cohorts (3 lg kg À1 and 5 lg kg À1 ). The thrombin generation assay (TGA) was performed by the use of PPP-Reagent LOW 1 pM tissue factor with the Calibrated Automated Thrombogram (Diagnostica Stago) [14] .
Immunogenicity evaluation
Samples for ADA, neutralizing antibody and FX activity were collected prior to dosing and on days 15, 29, and 43. The ADA assay followed a tiered approach of screening, confirmation, and titer/quantification with a validated, semiquantitative electrochemiluminescence assay. An ADA immune response was defined as a confirmed post-treatment positive assay result if negative at baseline, or at least a one dilution factor increase in titer relative to a positive baseline sample. Positive ADA samples were tested for cross-reactivity against native FX and native FXa, and analyzed for neutralizing antibody with a ligand binding-based assay. A neutralizing antibody response was defined as either a confirmed post-treatment positive neutralizing assay result or > 50% depletion of FX activity relative to baseline, in the absence of any other plausible explanation.
Statistical analyses
All volunteers who received at least one dose of FXa I16L or placebo were included in the safety analyses.
Results and discussion
Forty-nine healthy volunteers were enrolled. Six volunteers received each of the FXa I16L 0.1, 0.3, 1, 3 and 5 lg kg À1 doses; seven received the 2 lg kg À1 dose (one volunteer received < 80% of the planned dose and was replaced, and was not included in the PK or PD analyses); and 12 received placebo. Volunteers were non-smokers (84%) or ex-smokers (16%); most (90%) were white and 10% were black. All volunteers who were dosed completed the trial.
Safety
No deaths, SAEs, severe TEAEs or discontinuations because of TEAEs were reported during this trial. Thirtyfive TEAEs were reported by 27 volunteers across the different cohorts; only one TEAE, a headache of mild severity in one volunteer in the 5 lg kg À1 cohort, was reported as being treatment-related. Pharmacodynamics PD changes were observed for APTT, TAT complexes, F 1 + 2 , thrombin generation, and D-dimer. Dose-dependent APTT shortening occurred 2-5 min postdose, and returned to baseline by~2 h postdose at dose levels > 0.1 lg kg À1 (Fig. 1) . Changes in APTT closely paralleled the changes observed in drug exposure. Further clinical investigation is needed to determine whether this parameter may serve as a surrogate for FXa I16L plasma concentration. F 1 + 2 was maximally increased, dose dependently, at 5-40 min, returning to baseline by 24 h postdose (Fig. 2) . Maximal increases in TAT complexes were observed for the 3 lg kg À1 and 5 lg kg À1 dose treatment at~15 min, returning to baseline by 2 h (data not shown). Increased D-dimer levels were observed for the 2, 3 and 5 lg kg À1 dose levels at 2-4 h, and returned to baseline between 24 h and 48 h postdose (data not shown). Dose-dependent changes in TGA parameters were observed, with shortening of the lag time (Fig. 3A) and increases in peak thrombin (Fig. 3B) . No treatmentrelated changes were observed for PT/INR or FV activity. The lack of PT/INR modulation may reflect high sensitivity of this parameter to standard reagents, and a modified (dilute) PT test may be required to detect the pharmacologic effect of FXa I16L . A dose-dependent decrease in protein C activity was observed 2-5 min postdose when measured with the Staclot assay (data not shown). However, no apparent treatmentrelated change was observed in protein C activity measured with the chromogenic assay for the last two cohorts. Similarly, in the last two cohorts, a reduction in protein S activity was observed in the Staclot assay, whereas no apparent modulation was observed in a free protein S antigenic assay. Subsequent in vitro studies of FXa I16L spiked into normal plasma using a chromogenic assay for protein C activity indicated that the apparent depletion of protein C activity observed with the Staclot protein C clot-based assay reflects interference with the latter assay by the pharmacologic activity of FXa I16L (M. Bolt, F. Hua, K. Brennerman, J. Graves, S. Arkin, K. Criswell, unpublished data). , and pharmacologic activity was observed. No dose-limiting toxicity was observed, there was no clinically significant adverse modulation of laboratory safety parameters, and there was no occurrence of neutralizing antibody against FXa
I16L
. The single instance of an observed ADA was not associated with a TEAE, and was of no apparent clinical significance. Native FXa represents a critical endogenous homolog of FXa I16L ; consequently, neutralizing antibody immune responses to FXa I16L that are cross-reactive with native FXa represent a potential safety concern. Non-neutralizing ADAs have been observed in clinical trials of other coagulation products, including the FXa decoy protein andexanet alfa, with no apparent clinical correlates [15] [16] [17] . Additional clinical experience with FXa I16L is required to determine whether there is a risk of a clinically relevant antibody immune response.
In conclusion, the results from this trial support the investigation of FXa I16L as a treatment for acute hemorrhagic conditions in which short-acting hemostatic pharmacology may be of benefit and in which there would be low concern for a rebound effect as the drug effect decays. The full range of safe and tolerated doses of FXa I16L has not been defined, and further single-dose escalation is under way in a trial of FXa I16L in individuals with spontaneous ICH (NCT02687191).
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